274 related articles for article (PubMed ID: 25348954)
1. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.
Bai Y; Kim JY; Watters JM; Fang B; Kinose F; Song L; Koomen JM; Teer JK; Fisher K; Chen YA; Rix U; Haura EB
Cancer Res; 2014 Dec; 74(24):7217-7228. PubMed ID: 25348954
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Hammerman PS; Sos ML; Ramos AH; Xu C; Dutt A; Zhou W; Brace LE; Woods BA; Lin W; Zhang J; Deng X; Lim SM; Heynck S; Peifer M; Simard JR; Lawrence MS; Onofrio RC; Salvesen HB; Seidel D; Zander T; Heuckmann JM; Soltermann A; Moch H; Koker M; Leenders F; Gabler F; Querings S; Ansén S; Brambilla E; Brambilla C; Lorimier P; Brustugun OT; Helland A; Petersen I; Clement JH; Groen H; Timens W; Sietsma H; Stoelben E; Wolf J; Beer DG; Tsao MS; Hanna M; Hatton C; Eck MJ; Janne PA; Johnson BE; Winckler W; Greulich H; Bass AJ; Cho J; Rauh D; Gray NS; Wong KK; Haura EB; Thomas RK; Meyerson M
Cancer Discov; 2011 Jun; 1(1):78-89. PubMed ID: 22328973
[TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.
Beauchamp EM; Woods BA; Dulak AM; Tan L; Xu C; Gray NS; Bass AJ; Wong KK; Meyerson M; Hammerman PS
Mol Cancer Ther; 2014 Feb; 13(2):475-82. PubMed ID: 24296828
[TBL] [Abstract][Full Text] [Related]
4. Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.
Iwai LK; Payne LS; Luczynski MT; Chang F; Xu H; Clinton RW; Paul A; Esposito EA; Gridley S; Leitinger B; Naegle KM; Huang PH
Biochem J; 2013 Sep; 454(3):501-13. PubMed ID: 23822953
[TBL] [Abstract][Full Text] [Related]
5. NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.
Xu C; Buczkowski KA; Zhang Y; Asahina H; Beauchamp EM; Terai H; Li YY; Meyerson M; Wong KK; Hammerman PS
Mol Cancer Ther; 2015 Oct; 14(10):2382-2389. PubMed ID: 26206333
[TBL] [Abstract][Full Text] [Related]
6. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.
Pitini V; Arrigo C; Di Mirto C; Mondello P; Altavilla G
Lung Cancer; 2013 Oct; 82(1):171-2. PubMed ID: 23932362
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients.
Miao L; Wang Y; Zhu S; Shi M; Li Y; Ding J; Yang J; Ye Q; Cai H; Zhang D; Liu H; Song Y
BMC Cancer; 2014 May; 14():369. PubMed ID: 24885564
[TBL] [Abstract][Full Text] [Related]
8. Discoidin domain receptor 2 signaling networks and therapy in lung cancer.
Payne LS; Huang PH
J Thorac Oncol; 2014 Jun; 9(6):900-4. PubMed ID: 24828669
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
Day E; Waters B; Spiegel K; Alnadaf T; Manley PW; Buchdunger E; Walker C; Jarai G
Eur J Pharmacol; 2008 Dec; 599(1-3):44-53. PubMed ID: 18938156
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src stimulates intramolecular autophosphorylation and Shc signaling complex formation.
Yang K; Kim JH; Kim HJ; Park IS; Kim IY; Yang BS
J Biol Chem; 2005 Nov; 280(47):39058-66. PubMed ID: 16186108
[TBL] [Abstract][Full Text] [Related]
11. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.
Terai H; Tan L; Beauchamp EM; Hatcher JM; Liu Q; Meyerson M; Gray NS; Hammerman PS
ACS Chem Biol; 2015 Dec; 10(12):2687-96. PubMed ID: 26390252
[TBL] [Abstract][Full Text] [Related]
12. Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer.
Nicoś M; Powrózek T; Krawczyk P; Jarosz B; Pająk B; Sawicki M; Kucharczyk K; Trojanowski T; Milanowski J
Med Oncol; 2014 Oct; 31(10):176. PubMed ID: 25173530
[TBL] [Abstract][Full Text] [Related]
13. An essential role of discoidin domain receptor 2 (DDR2) in osteoblast differentiation and chondrocyte maturation via modulation of Runx2 activation.
Zhang Y; Su J; Yu J; Bu X; Ren T; Liu X; Yao L
J Bone Miner Res; 2011 Mar; 26(3):604-17. PubMed ID: 20734453
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
[TBL] [Abstract][Full Text] [Related]
15. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
17. Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
Terashima M; Togashi Y; Sato K; Mizuuchi H; Sakai K; Suda K; Nakamura Y; Banno E; Hayashi H; De Velasco MA; Fujita Y; Tomida S; Mitsudomi T; Nishio K
Clin Cancer Res; 2016 Jul; 22(14):3663-71. PubMed ID: 26826182
[TBL] [Abstract][Full Text] [Related]
18. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
Okamoto W; Okamoto I; Yoshida T; Okamoto K; Takezawa K; Hatashita E; Yamada Y; Kuwata K; Arao T; Yanagihara K; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 May; 9(5):1188-97. PubMed ID: 20406949
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Lee MS; Jung EA; An SB; Kim YJ; Oh DY; Song JY; Um SW; Han J; Choi YL
Cancer Res Treat; 2017 Oct; 49(4):1065-1076. PubMed ID: 28161936
[TBL] [Abstract][Full Text] [Related]
20. A new target for therapy in squamous cell carcinoma of the lung.
Ohashi K; Pao W
Cancer Discov; 2011 Jun; 1(1):23-4. PubMed ID: 22586316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
